Aug 2026· Cancer· Vol 132· 0 citations· 15 references
Medicine
Abstract
Magnetic resonance imaging radiomics shows promise in guiding the selection of patients most likely to benefit from the use of immune checkpoint inhibitor therapy in patients with very‐high‐risk, nonmuscle‐invasive bladder cancer. This work arrives at a moment of rapid expansion in bladder‐sparing therapeutics, even as biomarker‐guided patient selection remains conspicuously absent across the field.
Salvage focal therapy and radical prostatectomy show similar cancer-specific survival but differ in complications, and a biomarker-driven, patient-centered approach (including reirradiation) is needed for personalized management.
Take Home Message Ex vivo three-dimensional microtumor testing shows promise in predicting chemotherapy response in patients with bladder cancer within clinical timelines, highlighting its potential to serve as a clinical biomarker to guide treatment decision-making.
M. Scholtes, E. Koedoot, Lieke J. Ceton et al.· European Urology Open Scienc...· 0 citations
This retrospective observational cohort study assessed biomarker testing and guideline‐concordant matched first‐line therapy use and evaluated their associations with overall survival, diagnosis‐to‐treatment intervals, and 6‐month physical functioning in patients with advanced solid tumors.
Onur Baser, Yi-Jia Sun· Cancer Medicine· 0 citations
Current FDA-approved treatments for CCA include therapies targeting HER2, IDH1, FGFR2, and other key biomarkers, including therapies targeting HER2, IDH1, FGFR2, and other key biomarkers.
Augusto Almeida, Joao Manzi, Camila Hoff et al.· Translational Oncology· 1 citation
The current evidence on the clinical applications of circulating tumor DNA in muscle-invasive bladder cancer is summarized, including its role in prognosis, treatment selection, and surveillance, and future perspectives for integrating molecular monitoring into personalized cancer care are discussed.
M. Polito, L. Sisca, D. Caruso et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
